QuartrQuartr

PharmaEssentia: 2025 saw record revenue and profit, robust U.S. growth, and major expansion investments

Menos de 1 minuto de leitura

Revenue and net income surged in 2025, driven by U.S. medicine sales and improved margins. Major investments in manufacturing and clinical trials support future growth, while unresolved arbitration and customer concentration remain key risks.

Original document: PharmaEssentia Corp. [6446] Interim report — Mar. 27 2026

Aviso legal